2016 Focused Update On New Pharmacological Therapy For Heart Failure

2016 ACC/AHA/HFSA Focused Update On New Pharmacological Therapy For Heart Failure and 2016 ESC guidelines on the Diagnosis And Treatment Of Acute And Chronic Heart Failure NEERAJ VARYANI

NYHA FUNCTIONAL CLASSIFICATION

STAGES OF HEART FAILURE

DEFINITIONS OF HFrEF, HFmrEF and HFpEF

MAJOR CLINICAL TRIALS OF THERAPEUTIC INTERVENTION IN HFrEF

MAJOR CLINICAL TRIALS OF THERAPEUTIC INTERVENTION IN HFrEF

DATA SUPPLEMENT OF ACC/AHA/HFSA DOCUMENT ON ARNI

DATA SUPPLEMENT OF ACC/AHA/HFSA DOCUMENT ON COMPARISON OF ARNI WITH ACE

DATA SUPPLEMENT OF ACC/AHA/HFSA DOCUMENT ON COMPARISON OF ARNI WITH ACE

DATA SUPPLEMENT OF ACC/AHA/HFSA DOCUMENT FOR IVABRADINE

DATA SUPPLEMENT OF ACC/AHA/HFSA DOCUMENT ON IVABRADINE

DATA SUPPLEMENT OF ACC/AHA/HFSA DOCUMENT ON IVABRADINE

MAJOR TRIALS OF THERAPEUTIC INTERVENTION IN HFrEF

PHASE 2 AND PHASE 3 CLINICAL TRIALS IN HFmrEF AND HFpEF

CLASS OF RECOMMENDATIONS AND LEVEL OF EVIDENCE FOR THE ESC DOCUMENT

THERAPEUTIC ALGORITHM FOR A PATIENT WITH HFrEF

EVIDENCE BASED DOSES OF ARNI AND IVABRADINE

ESC GUIDELINES 2016 – WHAT IS THE PRESENT STATUS OF THESE NOVEL TREATMENTS

ACC/AHA/HFSA CLASS OF RECOMMENDATION AND LEVEL OF EVIDENCE

RAAS INHIBITION IN ACC/AHA/HFSA UPDATE 2016

CONTD..

ACC/AHA/HFSA 2016 RECOMMENDATION FOR IVABRADINE